2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. Reactive Oxygen Species
  4. BNTA

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.

For research use only. We do not sell to patients.

BNTA Chemical Structure

BNTA Chemical Structure

CAS No. : 685119-25-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 251 In-stock
Solution
10 mM * 1 mL in DMSO USD 251 In-stock
Solid
5 mg USD 250 In-stock
10 mg USD 400 In-stock
25 mg USD 770 In-stock
50 mg USD 1100 In-stock
100 mg USD 1480 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

BNTA Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation[1].

In Vitro

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes[1].
BNTA (0.1 μM; 2 d) increases SOX9 protein markedly[1].
BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes[1].
BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells[1].
BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes[1].
BNTA (0.01-10 μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes[1].
BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BNTA Related Antibodies

Cell Viability Assay[1]

Cell Line: Human OA chondrocytes
Concentration: 0.01, 0.1, 1, 10 μM
Incubation Time: 1, 3, 5, 7 d
Result: No toxicity was observed.

Western Blot Analysis[1]

Cell Line: Human OA chondrocytes
Concentration: 0.1 μM
Incubation Time: 2 d
Result: Elevated SOX9 protein compared with vehicle.
In Vivo

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SD rats weighing 80 g are induced by ACLT[1]
Dosage: 0.015, 0.15, 1.5 mg/kg
Administration: Intra-articular injection; twice a week for 4 and 8 weeks
Result: Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.
Molecular Weight

456.76

Formula

C17H11BrClNO3S2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=C(Br)SC=C1S(=O)(C2=CC=CC=C2)=O)C3=CC=CC=C3Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (218.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1893 mL 10.9467 mL 21.8933 mL
5 mM 0.4379 mL 2.1893 mL 4.3787 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1893 mL 10.9467 mL 21.8933 mL 54.7333 mL
5 mM 0.4379 mL 2.1893 mL 4.3787 mL 10.9467 mL
10 mM 0.2189 mL 1.0947 mL 2.1893 mL 5.4733 mL
15 mM 0.1460 mL 0.7298 mL 1.4596 mL 3.6489 mL
20 mM 0.1095 mL 0.5473 mL 1.0947 mL 2.7367 mL
25 mM 0.0876 mL 0.4379 mL 0.8757 mL 2.1893 mL
30 mM 0.0730 mL 0.3649 mL 0.7298 mL 1.8244 mL
40 mM 0.0547 mL 0.2737 mL 0.5473 mL 1.3683 mL
50 mM 0.0438 mL 0.2189 mL 0.4379 mL 1.0947 mL
60 mM 0.0365 mL 0.1824 mL 0.3649 mL 0.9122 mL
80 mM 0.0274 mL 0.1368 mL 0.2737 mL 0.6842 mL
100 mM 0.0219 mL 0.1095 mL 0.2189 mL 0.5473 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BNTA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BNTA685119-25-9Reactive Oxygen SpeciesextracellularmatrixECMmodulatorypropertiescartilagechondrocytessuperoxidedismutase3SOD3osteoarthritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BNTA
Cat. No.:
HY-136651
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.